Forte Biosciences (FBRX) Announces Proposed Public Offering of Common Stock

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering. Forte intends to use the net proceeds of the offering for working capital and general corporate purposes, which include, but are not limited to, the funding of clinical development of, and pursuing regulatory approval for, its product candidates and, and general and administrative expenses. All of the shares of common stock are being offered by Forte. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Ladenburg Thalmann, Truist Securities and Chardan are acting as joint book-running managers for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as a co-manager for the offering.

A shelf registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on May 11, 2018 and declared effective by the SEC on May 23, 2018. The proposed offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained from Ladenburg Thalmann & Co. Inc., Prospectus Department, 277 Park Avenue, 26th Floor, New York, New York 10172 or by email at [email protected],Truist Securities, Inc., Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta, Georgia 30326 or by email at [email protected], and Chardan Capital Markets, LLC, 17 State Street, Suite 2100, New York, NY 10004 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

You May Also Be Interested In

• Rainier Acquisition prices $75M IPO on Nasdaq
• SEC clears VerifyMe and OpenWorld merger registration statement
• Invitation Homes names James Curl as chief technology officer